Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker AMPH · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Jul 22, 2026 | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimi… NCT07560150 · Pharmacokinetics, Pharmacodynamics I004, NovoLog | AMPH Amphastar Pharmaceuticals, Inc. | Phase 2/3 | Completed | 62 | Jun 22, 2026 | Registry ↗ |
| Mar 5, 2026 | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimi… NCT05539872 · Pharmacokinetics, Pharmacodynamics I004, NovoLog | AMPH Amphastar Pharmaceuticals, Inc. | Phase 2/3 | Completed | 69 | Jan 29, 2023 | Registry ↗ |
| Mar 30, 2021 | Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epineph… NCT04207840 · Pharmacokinetics, Epinephrine Epinephrine (0.125 mg/inhalation), Epinephrine Injection Au… | AMPH Amphastar Pharmaceuticals, Inc. | Phase 4 | Completed | 28 | Dec 20, 2019 | Registry ↗ |
| Sep 25, 2018 | Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers NCT01143051 · Asthma epinephrine inhalation aerosol, epinephrine inhalation aero… | AMPH Amphastar Pharmaceuticals, Inc. | Phase 1/2 | Completed | 24 | Jun 2010 | Registry ↗ |
| Jul 31, 2018 | Evaluation of Efficacy and Safety of E004 in Children With Asthma NCT01460511 · Asthma E004 (Epinephrine Inhalation Aerosol) HFA-MDI, Placebo-HFA | AMPH Amphastar Pharmaceuticals, Inc. | Phase 3 | Completed | 70 | Mar 2012 | Registry ↗ |
| May 16, 2018 | Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients. NCT01025648 · Asthma E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E0… | AMPH Amphastar Pharmaceuticals, Inc. | Phase 1/2 | Terminated | 9 | Dec 2009 | Registry ↗ |
| Jul 25, 2017 | Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics NCT01188577 · Asthma, Bronchospasm Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation… | AMPH Amphastar Pharmaceuticals, Inc. | Phase 1/2 | Completed | 23 | Sep 2010 | Registry ↗ |
| Jul 2, 2017 | Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of… NCT01189396 · Asthma, Bronchospasm A006, Placebo DPI | AMPH Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | 27 | Dec 2010 | Registry ↗ |
| May 19, 2017 | Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation NCT01581177 · Asthma Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh | AMPH Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | 23 | Jul 2012 | Registry ↗ |
| Apr 19, 2017 | Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers NCT02271334 · Asthma A006 DPI, A006 DPI | AMPH Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | 22 | Oct 2014 | Registry ↗ |
| Apr 19, 2017 | Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation NCT02210806 · Asthma A006 DPI, A006 DPI | AMPH Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | 22 | Sep 2014 | Registry ↗ |
| Apr 19, 2017 | Dose-Ranging Study of A006 DPI, in Adult Asthma Patients NCT01174732 · Asthma, Bronchospasm albuterol inhalation powder, albuterol inhalation powder | AMPH Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | 26 | Oct 2010 | Registry ↗ |
| Feb 13, 2017 | Safety Study in Adolescent and Adult Patients With Asthma NCT01476904 · Asthma Placebo, Primatene Mist | AMPH Amphastar Pharmaceuticals, Inc. | Phase 3 | Completed | 208 | Apr 2012 | Registry ↗ |
| Jan 20, 2017 | Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) NCT01689363 · Allergic Skin Reaction Hyaluronidase, Histamine | AMPH Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | 253 | Nov 2012 | Registry ↗ |
| Mar 17, 2016 | Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults NCT01737892 · Asthma Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhala… | AMPH Amphastar Pharmaceuticals, Inc. | Phase 1/2 | Terminated | 21 | Nov 2012 | Registry ↗ |
| Mar 17, 2016 | Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS NCT01255709 · Asthma Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA | AMPH Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | 24 | Jan 2011 | Registry ↗ |
| Mar 11, 2016 | Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma NCT01737905 · Asthma Epinephrine HFA-MDI (E004), Placebo-HFA | AMPH Amphastar Pharmaceuticals, Inc. | Phase 3 | Completed | 28 | Mar 2013 | Registry ↗ |
| Mar 11, 2016 | Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients NCT01357642 · Asthma Epinephrine inhalation aerosol, Placebo | AMPH Amphastar Pharmaceuticals, Inc. | Phase 3 | Completed | 373 | Nov 2011 | Registry ↗ |
18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:21 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances